Last $0.59 USD
Change Today +0.0455 / 8.43%
Volume 87.8K
NBY On Other Exchanges
As of 2:24 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - $1.38
52 Week Low
02/27/15 - $0.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It offers Aganocide compounds, including auriclosene irrigation solution to reduce urinary catheter blockage and encrustation; an eye drop formulation of auriclosene for treating adenoviral conjunctivitis; and a gel formulation of auriclosene for treating impetigo, a highly contagious skin infection. The company also provides NeutroPhase, a skin and wound cleanser for non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

29 Employees
Last Reported Date: 03/6/14
Founded in 2000

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $440.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.7K
Senior Vice President of Business & Corporate...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2013.

novabay pharmaceuticals inc (NBY) Key Developments

NovaBay Pharmaceuticals, Inc. Signs Avenova Distribution Agreement with Cardinal Health, Inc

NovaBay Pharmaceuticals, Inc. announced that it has signed a nationwide distribution agreement with Cardinal Health. Under the agreement, Cardinal Health will carry and distribute NovaBay’s Avenova, a prescription lid and lash hygiene product for the lid hygiene management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye, to independent and retail chain pharmacies. The agreement is effective immediately and NovaBay is working with Cardinal Health to ensure sufficient product stocking to meet Avenova demand.

NovaBay Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 01:00 PM

NovaBay Pharmaceuticals, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 01:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Glenn Moro, Vice President of Sales & Marketing - Avenova, Tom Paulson, CFO.

NovaBay Pharmaceuticals, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 04:15 PM

NovaBay Pharmaceuticals, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 04:15 PM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.59 USD +0.0455

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies

Industry Analysis


Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.6x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at